The funding validates investor confidence in AI‑enabled drug discovery and positions Cassidy Bio to speed up gene‑editing therapy pipelines, potentially reshaping R&D efficiency in the biotech sector.
Tel Aviv‑based biotech Cassidy Bio announced an $8 million seed round to fund its AI‑driven genomic foundation model for gene‑editing therapies. The round was led by Ahren Innovation Capital with participation from Lool Ventures, 10D VC and AION Lab’s venture seeding track backed by AstraZeneca and Merck KGaA.
Comments
Want to join the conversation?
Loading comments...